论文信息 - Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. - 字舞流文

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

M. Atkins | E. Plimack | B. Melichar | B. Rini | B. Alekseev | T. Powles | J. Bedke | R. McDermott | L. Wood | D. Soulières | H. Hammers | Y. Shparyk | S. Tartas | E. Jensen | B. Haber | C. Kondoh | P. Langiewicz | C. Silber | Mei Chen | L. Wood